{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:59:46Z","timestamp":1772135986665,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hungarian Government's Higher Education Institutional Excellence Programme project","award":["20765-3\/2018\/FEKUTSTRAT"],"award-info":[{"award-number":["20765-3\/2018\/FEKUTSTRAT"]}]},{"name":"Hungarian Science Foundation National Research, Development and Innovation Office Grants","award":["128322"],"award-info":[{"award-number":["128322"]}]},{"name":"Hungarian Government's Operative Programme","award":["GINOP-2.3.2-15-2016-00022"],"award-info":[{"award-number":["GINOP-2.3.2-15-2016-00022"]}]},{"name":"Hungarian Ministry of Innovation and Technology's Thematic Excellence Program"},{"name":"European Union's 7th Framework Programme","award":["Nr. 606614 (CLI)"],"award-info":[{"award-number":["Nr. 606614 (CLI)"]}]},{"name":"Horizon 2020","award":["Nr. 739593 (HCEMM)"],"award-info":[{"award-number":["Nr. 739593 (HCEMM)"]}]},{"DOI":"10.13039\/501100002332","name":"Semmelweis University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cerenkov luminescence imaging (CLI) is a promising approach to image-guided surgery and pathological sampling. It could offer additional advantages when combined to whole-body isotope tomographies. We aimed to obtain evidence of its applicability in lymphoma patho-diagnostics, thus we decided to investigate the radiodiagnostic potential of\n                    <jats:italic>combined<\/jats:italic>\n                    PET or SPECT\/CLI in an experimental, novel spontaneous high-grade B-cell lymphoma mouse model (Bc.DLFL1). We monitored the lymphoma dissemination at early stage, and at clinically relevant stages such as advanced stage and terminal stage with in vivo 2-deoxy-2-[\n                    <jats:sup>18<\/jats:sup>\n                    F]fluoro-\n                    <jats:sc>d<\/jats:sc>\n                    -glucose (FDG) positron emission tomography (PET)\/magnetic resonance imaging (MRI) and\n                    <jats:sup>67<\/jats:sup>\n                    Ga-citrate single photon emission computed tomography (SPECT)\/MRI. In vivo imaging was combined with ex vivo high resolution CLI. The use of CLI with\n                    <jats:sup>18<\/jats:sup>\n                    F-Fluorine (F-18) and\n                    <jats:sup>67<\/jats:sup>\n                    Ga-Gallium isotopes in the selection of infiltrated lymph nodes for tumor staging and pathology was thus tested. At advanced stage, FDG PET\/MRI plus ex vivo CLI allowed accurate detection of FDG accumulation in lymphoma-infiltrated tissues. At terminal stage we detected tumorous lymph nodes with SPECT\/MRI and we could report in vivo detection of the Cerenkov light emission of\n                    <jats:sup>67<\/jats:sup>\n                    Ga. CLI with\n                    <jats:sup>67<\/jats:sup>\n                    Ga-citrate revealed lymphoma accumulation in distant lymph node locations, unnoticeable with only MRI. Flow cytometry and immunohistochemistry confirmed these imaging results. Our study promotes the combined use of PET and CLI in preclinical studies and clinical practice. Heterogeneous FDG distribution in lymph nodes, detected at sampling surgery, has implications for tissue pathology processing and it could direct therapy. The results with\n                    <jats:sup>67<\/jats:sup>\n                    Ga also point to the opportunities to further apply suitable SPECT radiopharmaceuticals for CLI.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-03505-3","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T06:03:55Z","timestamp":1639461835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["In situ lymphoma imaging in a spontaneous mouse model using the Cerenkov Luminescence of F-18 and Ga-67 isotopes"],"prefix":"10.1038","volume":"11","author":[{"given":"Zsombor","family":"Ritter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katalin","family":"Z\u00e1mb\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Balogh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e1vid","family":"Sz\u00f6ll\u0151si","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinkai","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1kos","family":"Bal\u00e1zs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Taba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e1niel","family":"Dezs\u0151","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ildik\u00f3","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussain","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Tuch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunal","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolett","family":"Heged\u0171s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tibor","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kriszti\u00e1n","family":"Szigeti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domokos","family":"M\u00e1th\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erzs\u00e9bet","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"key":"3505_CR1","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3324\/haematol.2016.148809","volume":"101","author":"AM Perry","year":"2016","unstructured":"Perry, A. M. et al. Non-Hodgkin lymphoma in the developing world: Review of 4539 cases from the international non-Hodgkin lymphoma classification project. Haematologica 101, 1244\u20131250 (2016).","journal-title":"Haematologica"},{"key":"3505_CR2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.critrevonc.2012.12.009","volume":"87","author":"M Martelli","year":"2013","unstructured":"Martelli, M. et al. Diffuse large B-cell lymphoma. Crit. Rev. Oncol. Hematol. 87, 146\u2013171 (2013).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"3505_CR3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","volume":"50","author":"S Li","year":"2018","unstructured":"Li, S., Young, K. H. & Medeiros, J. L. Diffuse large B-cell lymphoma. Pathology 50, 74\u201387 (2018).","journal-title":"Pathology"},{"key":"3505_CR4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503\u2013511 (2000).","journal-title":"Nature"},{"key":"3505_CR5","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo, E. et al. The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications. Blood 117, 5019\u20135032 (2011).","journal-title":"Blood"},{"key":"3505_CR6","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow, S. H. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127, 2375\u20132390 (2016).","journal-title":"Blood"},{"key":"3505_CR7","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz, R. et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N. Engl. J. Med. 378, 1396\u20131407 (2018).","journal-title":"N. Engl. J. Med."},{"key":"3505_CR8","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1002\/cncr.32145","volume":"125","author":"JS Abramson","year":"2019","unstructured":"Abramson, J. S. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?. Cancer 125, 3111\u20133120 (2019).","journal-title":"Cancer"},{"key":"3505_CR9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.14136","volume":"174","author":"S Chaganti","year":"2016","unstructured":"Chaganti, S. et al. Guidelines for the management of diffuse large B-cell lymphoma. Br. J. Haematol. 174, 43\u201356 (2016).","journal-title":"Br. J. Haematol."},{"key":"3505_CR10","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.blre.2016.06.003","volume":"30","author":"PF Caimi","year":"2016","unstructured":"Caimi, P. F., Hill, T. B., Hsi, E. D. & Smith, R. M. Clinical approach to diffuse large B cell lymphoma. Blood Rev. 30, 477\u2013491 (2016).","journal-title":"Blood Rev."},{"key":"3505_CR11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","volume":"25","author":"ME Juweid","year":"2007","unstructured":"Juweid, M. E. et al. Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J. Clin. Oncol. 25, 571\u2013578 (2007).","journal-title":"J. Clin. Oncol."},{"key":"3505_CR12","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma\u2014The Lugano Classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."},{"key":"3505_CR13","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington, S. F. et al. The role of imaging in the staging and response assessment of lymphoma: Consensus of the ICML Imaging Working Group. J. Clin. Oncol. 32, 3048\u20133058 (2014).","journal-title":"J. Clin. Oncol."},{"key":"3505_CR14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1053\/j.semnuclmed.2017.09.007","volume":"48","author":"BD Cheson","year":"2017","unstructured":"Cheson, B. D. PET\/CT in Lymphoma: Current overview and future directions. Semin. Nucl. Med. 48, 76\u201381 (2017).","journal-title":"Semin. Nucl. Med."},{"key":"3505_CR15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/j.semnuclmed.2017.09.005","volume":"48","author":"L Kostakoglu","year":"2018","unstructured":"Kostakoglu, L. & Chauvie, S. Metabolic tumor volume metrics in lymphoma. Semin. Nucl. Med. 48, 50\u201366 (2018).","journal-title":"Semin. Nucl. Med."},{"key":"3505_CR16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cpet.2019.03.002","volume":"14","author":"L Kostakoglu","year":"2019","unstructured":"Kostakoglu, L. & Chauvie, S. PET-derived quantitative metrics for response and prognosis in lymphoma. PET Clin. 14, 317\u2013329 (2019).","journal-title":"PET Clin."},{"key":"3505_CR17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.semnuclmed.2017.09.001","volume":"48","author":"TC El-Galaly","year":"2017","unstructured":"El-Galaly, T. C., Gormsen, L. C. & Hutchings, M. PET\/CT for staging; past, present, and future. Semin. Nucl. Med. 48, 4\u201316 (2017).","journal-title":"Semin. Nucl. Med."},{"key":"3505_CR18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cpet.2015.08.001","volume":"11","author":"JJ Cerci","year":"2016","unstructured":"Cerci, J. J., Tabacchi, E. & Bogoni, M. Fluorodeoxyglucose-PET\/computed tomography\u2013guided biopsy. PET Clin. 11, 57\u201364 (2016).","journal-title":"PET Clin."},{"key":"3505_CR19","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00259-016-3560-9","volume":"44","author":"CG England","year":"2017","unstructured":"England, C. G., Rui, L. & Cai, W. Lymphoma: Current status of clinical and preclinical imaging with radiolabeled antibodies. Eur. J. Nucl. Med. Mol. Imaging 44, 517\u2013532 (2017).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"3505_CR20","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s12253-015-0025-6","volume":"22","author":"D Vojkovics","year":"2016","unstructured":"Vojkovics, D. et al. Isolation and characterization of a murine spontaneous high-grade follicular lymphoma with restricted in vivo spreading-a model for lymphatic metastasis via the mesentery. Pathol. Oncol. Res. 22, 421\u2013430 (2016).","journal-title":"Pathol. Oncol. Res."},{"key":"3505_CR21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4049\/jimmunol.1900851","volume":"204","author":"X Jia","year":"2020","unstructured":"Jia, X. et al. Foliate lymphoid aggregates as novel forms of serous lymphocyte entry sites of peritoneal B cells and high-grade B cell lymphomas. J. Immunol. 204, 23\u201336 (2020).","journal-title":"J. Immunol."},{"key":"3505_CR22","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1098\/rsta.2011.0271","volume":"369","author":"GS Mitchell","year":"2011","unstructured":"Mitchell, G. S., Gill, R. K., Boucher, D. L., Li, C. & Cherry, S. R. In vivo cerenkov luminescence imaging: A new tool for molecular imaging. Philos. Trans. A. 369, 4605\u20134619 (2011).","journal-title":"Philos. Trans. A."},{"key":"3505_CR23","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00259-013-2408-9","volume":"40","author":"PTK Chin","year":"2013","unstructured":"Chin, P. T. K. et al. Optical imaging as an expansion of nuclear medicine: Cerenkov-based luminescence vs fluorescence-based luminescence. Eur. J. Nucl. Med. Mol. Imaging. 40, 1283\u20131291 (2013).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"3505_CR24","doi-asserted-by":"publisher","first-page":"e31402","DOI":"10.1371\/journal.pone0031402","volume":"7","author":"BJ Beattie","year":"2012","unstructured":"Beattie, B. J. et al. Quantitative modeling of Cerenkov Light production efficiency from medical radionuclides. PLoS ONE 7, e31402. https:\/\/doi.org\/10.1371\/journal.pone0031402 (2012).","journal-title":"PLoS ONE"},{"key":"3505_CR25","unstructured":"Beattie B. J. Improvements in the robustness and accuracy of bioluminescence tomographic reconstructions of distributed sources within small animals. Eng. Dr. Dissertation, Columbia University (2018)"},{"key":"3505_CR26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","volume":"37","author":"R Boellaard","year":"2010","unstructured":"Boellaard, R. et al. FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: Version 1.0. Eur. J. Nucl. Med. Mol. Imaging. 37, 181\u2013200 (2010).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"3505_CR27","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1007\/s00259-011-1899-5","volume":"38","author":"P Cheebsumon","year":"2011","unstructured":"Cheebsumon, P. et al. Impact of [18F]FDG PET imaging parameters on automatic tumour delineation: Need for improved tumour delineation methodology. Eur. J. Nucl. Med. Mol. Imaging. 38, 2136\u20132144 (2011).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"3505_CR28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00259-012-2247-0","volume":"40","author":"S Chicklore","year":"2013","unstructured":"Chicklore, S. et al. Quantifying tumour heterogeneity in 18F-FDG PET\/CT imaging by texture analysis. Eur. J. Nucl. Med. Mol. Imaging. 40, 133\u2013140 (2013).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"3505_CR29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejmp.2014.12.003","volume":"31","author":"AE Spinelli","year":"2015","unstructured":"Spinelli, A. E. & Boschi, F. Novel biomedical applications of Cerenkov radiation and radioluminescence imaging. Physica Med. 31, 120\u2013129 (2015).","journal-title":"Physica Med."},{"key":"3505_CR30","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1007\/s00259-020-04783-1","volume":"47","author":"JO Heuvel","year":"2020","unstructured":"Heuvel, J. O. et al. 68Ga-PSMA Cerenkov luminescence imaging in primary prostate cancer: First-in-man series. Eur. J. Nucl. Med. Mol. Imaging. 47, 2624\u20132632 (2020).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"3505_CR31","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2967\/jnumed.116.181032","volume":"58","author":"MR Grootendorst","year":"2017","unstructured":"Grootendorst, M. R. et al. Intraoperative assessment of tumor resection margins in breast-conserving surgery using 18F-FDG Cerenkov Luminescence Imaging: A first-in-human feasibility study. J. Nucl. Med. 58, 891\u2013898 (2017).","journal-title":"J. Nucl. Med."},{"key":"3505_CR32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2967\/jnumed.116.178780","volume":"58","author":"JW D\u2019Souza","year":"2017","unstructured":"D\u2019Souza, J. W. et al. Cerenkov luminescence imaging as a modality to evaluate antibody-based PET radiotracers. J. Nucl. Med. 58, 175\u2013180 (2017).","journal-title":"J. Nucl. Med."},{"key":"3505_CR33","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/annonc\/mdq389","volume":"22","author":"JA Dorth","year":"2011","unstructured":"Dorth, J. A. et al. The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG\u2013PET or gallium-67 scans. Ann. Oncol. 22, 405\u2013410 (2011).","journal-title":"Ann. Oncol."},{"key":"3505_CR34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2310\/7290.2010.00047","volume":"10","author":"JP Holland","year":"2011","unstructured":"Holland, J. P., Normand, G., Ruggiero, A., Lewis, J. S. & Grimm, J. A. Intraoperative imaging of positron emission tomographic radiotracers using Cerenkov luminescence emissions. Mol. Imaging. 10, 177\u2013186 (2011).","journal-title":"Mol. Imaging."},{"key":"3505_CR35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41181-019-0075-2","volume":"4","author":"A Ku","year":"2019","unstructured":"Ku, A., Facca, V. J., Cai, Z. & Reilly, R. M. Auger electrons for cancer therapy\u2014A review. EJNMMI Radiopharm. Chem. 4, 27 (2019).","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"3505_CR36","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40336-016-0183-x","volume":"4","author":"MR Grootendorst","year":"2016","unstructured":"Grootendorst, M. R., Kothari, A. C., Tuch, D. S. & Purushotham, A. Cerenkov luminescence imaging (CLI) for image-guided cancer surgery. Clin. Transl. Imaging. 4, 353\u2013366 (2016).","journal-title":"Clin. Transl. Imaging."},{"key":"3505_CR37","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.semnuclmed.2018.02.007","volume":"48","author":"R Tamura","year":"2018","unstructured":"Tamura, R., Pratt, E. C. & Grimm, J. Innovations in nuclear imaging instrumentation: Cerenkov imaging. Semin. Nucl. Med. 48, 359\u2013366 (2018).","journal-title":"Semin. Nucl. Med."},{"key":"3505_CR38","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.nano.2018.12.017","volume":"17","author":"Z Zhang","year":"2019","unstructured":"Zhang, Z., Cai, M., Bao, C., Hu, Z. & Tian, J. Endoscopic Cerenkov luminescence imaging and image-guided tumor resection on hepatocellular carcinoma-bearing mouse models. Nanomed. Nanotech. Biol. Med. 17, 62\u201370 (2019).","journal-title":"Nanomed. Nanotech. Biol. Med."},{"key":"3505_CR39","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.7150\/thno.23709","volume":"8","author":"DY Lewis","year":"2018","unstructured":"Lewis, D. Y. et al. [18F]Fluoroethyltyrosine-induced Cerenkov luminescence improves image-guided surgical resection of glioma. Theranostics 8, 3991\u20134002 (2018).","journal-title":"Theranostics"},{"key":"3505_CR40","doi-asserted-by":"publisher","first-page":"e201800093","DOI":"10.1002\/jbio.201800093","volume":"11","author":"F Boschi","year":"2018","unstructured":"Boschi, F., De Sanctis, F., Ugel, S. & Spinelli, A. E. T-cell tracking using Cerenkov and radioluminescence imaging. J. Biophoton. 11, e201800093. https:\/\/doi.org\/10.1002\/jbio.201800093 (2018).","journal-title":"J. Biophoton."},{"key":"3505_CR41","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1117\/1.JBO.21.5.050502","volume":"21","author":"AE Spinelli","year":"2016","unstructured":"Spinelli, A. E. et al. Cerenkov and radioluminescence imaging of brain tumor specimens during neurosurgery. J. Biomed. Opt. 21, 5 (2016).","journal-title":"J. Biomed. Opt."},{"key":"3505_CR42","first-page":"2089","volume":"41","author":"SV Govindan","year":"2000","unstructured":"Govindan, S. V. et al. Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: Comparison of auger electron emitters with \u03b2-particle emitters. J. Nucl. Med. 41, 2089\u20132097 (2000).","journal-title":"J. Nucl. Med."},{"key":"3505_CR43","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.nucmedbio.2014.03.026","volume":"41","author":"E Koumarianou","year":"2014","unstructured":"Koumarianou, E. et al. Radiolabeling and in vitro evaluation of 67Ga-NOTA-modular nanotransporter\u2014A potential auger electron emitting EGFR-targeted radiotherapeutic. Nucl. Med. Biol. 41, 441\u2013449 (2014).","journal-title":"Nucl. Med. Biol."},{"key":"3505_CR44","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40336-020-00359-z","volume":"8","author":"D Paez","year":"2020","unstructured":"Paez, D., Giammarile, F. & Orellana, P. Nuclear medicine: A global perspective. Clin. Transl. Imaging. 8, 51\u201353 (2020).","journal-title":"Clin. Transl. Imaging."},{"key":"3505_CR45","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1600-0609.1993.tb00631.x","volume":"51","author":"PC Huijgens","year":"1993","unstructured":"Huijgens, P. C., Jonkhoff, A. R., Hoekstra, O. S., Ossenkoppele, G. J. & Teule, G. J. J. Therapeutic potential of intravenous 67-gallium in non-Hodgkin\u2019s lymphoma. Eur. J. Haematol. 51, 206\u2013208 (1993).","journal-title":"Eur. J. Haematol."},{"key":"3505_CR46","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/bjc.1995.544","volume":"72","author":"AR Jonkhoff","year":"1995","unstructured":"Jonkhoff, A. R., Plaizier, M. A. B. D., Ossenkoppele, G. J., Teule, G. J. J. & Huijgens, P. C. High-dose gallium-67 therapy in patients with relapsed acute leukaemia: A feasibility study. Br. J. Cancer 72, 1541\u20131546 (1995).","journal-title":"Br. J. Cancer"},{"key":"3505_CR47","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00259-003-1164-7","volume":"30","author":"E Even-Sapir","year":"2003","unstructured":"Even-Sapir, E. & Israel, O. Gallium-67 scintigraphy: A cornerstone in functional imaging of lymphoma. Eur. J. Nucl. Med. Mol. Imaging 30, 65\u201381 (2003).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"3505_CR48","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s12185-017-2337-7","volume":"107","author":"M Sakurai","year":"2018","unstructured":"Sakurai, M. et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography with gallium-67 scintigraphy in the initial clinical staging of diffuse large B-cell lymphoma. Int. J Hematol. 107, 194\u2013200 (2018).","journal-title":"Int. J Hematol."},{"key":"3505_CR49","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00259-016-3560-9","volume":"44","author":"G Christopher","year":"2017","unstructured":"Christopher, G., Rui, L. & Cai, W. Lymphoma: Current status of clinical and preclinical imaging with radiolabeled antibodies. Eur. J. Nucl. Med. Mol. Imaging 44, 517\u2013532 (2017).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"3505_CR50","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.nucmedbio.2016.10.008","volume":"46","author":"MF Bin Othman","year":"2017","unstructured":"Bin Othman, M. F., Mitry, N. R., Lewington, V. J., Blower, P. J. & Terry, S. Y. A. Re-assessing gallium-67 as a therapeutic radionuclide. Nucl. Med. Biol. 46, 12\u201318 (2017).","journal-title":"Nucl. Med. Biol."},{"key":"3505_CR51","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.nucmedbio.2019.12.004","volume":"80\u201381","author":"B Othman","year":"2020","unstructured":"Othman, B. et al. In vitro cytotoxicity of Auger electron-emitting [67Ga] Ga-trastuzumab. Nucl. Med. Biol. 80\u201381, 57\u201364 (2020).","journal-title":"Nucl. Med. Biol."},{"key":"3505_CR52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10555-011-9331-y","volume":"31","author":"G Banfalvi","year":"2012","unstructured":"Banfalvi, G. Role of parathymic lymph nodes in metastatic tumor development. Cancer Met. Rev. 31, 89\u201397 (2012).","journal-title":"Cancer Met. Rev."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03505-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03505-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03505-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T13:03:35Z","timestamp":1670072615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03505-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,14]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["3505"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-03505-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-289118\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,14]]},"assertion":[{"value":"1 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DT is Director and Shareholder of Lightpoint Medical Ltd., KV is employee of Lightpoint Medical Ltd. DM is CEO and Shareholder of CROmed Ltd. All the other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24002"}}